KD 247

Drug Profile

KD 247

Alternative Names: Anti-HIV monoclonal antibody - Kaketsuken (Chemo-Sero Therapeutic Research Institute); Anti-V3 humanised antibody KD-247; KD-247

Latest Information Update: 21 Sep 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kaketsuken
  • Developer Kaketsuken; Kumamoto University; University of Missouri-Columbia
  • Class Antiretrovirals; Monoclonal antibodies
  • Mechanism of Action HIV envelope protein gp120 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Phase I HIV-1 infections

Most Recent Events

  • 21 Sep 2010 KD 247 is still in a Phase-I trial for HIV-1 infections in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top